北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (1): 150-158. doi: 10.19723/j.issn.1671-167X.2021.01.023
CAO Ze,WANG Le-tong,LIU Zhen-ming()
摘要:
目的: 分析严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)的全长测序信息中,其刺突蛋白(Spike protein,S蛋白)的自发突变情况,以及S蛋白突变前后与宿主相关受体蛋白质和潜在抗病毒药物结合能力的变化。方法: 对SARS-CoV-2的一级序列进行生物信息学分析,确定高频突变位点,利用PolyPhen-2软件逐一对S蛋白突变后的功能进行预测和分析。使用SWISS-MODEL系统对突变后的S蛋白序列进行基于相似性的同源建模,利用ZDOCK程序对所建模型与血管紧张素转化酶2(angiotensin-converting enzyme 2,ACE2)、二肽基肽酶-4(dipeptidyl peptidase-4,DPP4,又称CD26)以及氨基肽酶N(aminopeptidase N,APN,又称CD13)进行蛋白质对接,用FiPD软件对结合能力评价结果进行分析,最后采用AutoDock-Chimera 1.14对突变前后的S蛋白与潜在抗病毒药物的结合能力进行预测和比较分析。结果: S蛋白的某些特定区域发生突变能够更大程度地影响其功能,突变之后,S蛋白与ACE2的结合能力趋向于减弱,而与DPP4的结合能力趋向于增强,与APN的结合能力无显著变化。抗人类免疫缺陷病毒(human immunodeficiency virus,HIV)药物aplaviroc与S蛋白的亲和能力显著高于其他候选小分子药物。结论: SARS-CoV-2在自然状态下发生突变,其S蛋白第400~1 100个氨基酸的区域为点突变高频区,突变趋势为与DPP4结合力增强,DPP4可能成为SARS-CoV-2感染细胞的新受体,aplaviroc可能成为一种SARS-CoV-2治疗药物的潜在选择。
中图分类号:
[1] |
Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human patho-genic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV[J]. J Med Virol, 2020,92(5):491-494.
doi: 10.1002/jmv.25709 pmid: 32056249 |
[2] | Wang C, Liu Z, Chen Z, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis[J]. J Med Virol, 2020,10(1002):25762. |
[3] |
Ma Y, Wu L, Shaw N, et al. Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex[J]. Proc Natl Acad Sci USA, 2015,112(30):9436-9441.
doi: 10.1073/pnas.1508686112 pmid: 26159422 |
[4] |
Kim D, Lee JY, Yang JS, et al. The architecture of SARS-CoV-2 transcriptome[J]. Cell, 2020,181(4):914-921.
doi: 10.1016/j.cell.2020.04.011 pmid: 32330414 |
[5] |
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020,395(10224):565-574.
doi: 10.1016/S0140-6736(20)30251-8 pmid: 32007145 |
[6] |
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020,579(7798):270-273.
doi: 10.1038/s41586-020-2012-7 pmid: 32015507 |
[7] |
Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2[J]. Science, 2020,367(6485):1444-1448.
doi: 10.1126/science.abb2762 pmid: 32132184 |
[8] |
Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein[J]. Cell, 2020,181(2):281-292.
doi: 10.1016/j.cell.2020.02.058 pmid: 32155444 |
[9] |
Chan CM, Chu H, Wang Y, et al. Carcinoembryonic antigen-related cell adhesion molecule 5 is an important surface attachment factor that facilitates entry of Middle East respiratory syndrome coronavirus[J]. J Virol, 2016,90(20):9114-9127.
doi: 10.1128/JVI.01133-16 pmid: 27489282 |
[10] |
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic corona-viruses[J]. Nat Rev Microbiol, 2019,17(3):181-192.
doi: 10.1038/s41579-018-0118-9 pmid: 30531947 |
[11] |
Chu H, Chan CM, Zhang X, et al. Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells[J]. J Biol Chem, 2018,293(30):11709-11726.
doi: 10.1074/jbc.RA118.001897 pmid: 29887526 |
[12] |
Satija N, Lal SK. The molecular biology of SARS coronavirus[J]. Ann N Y Acad Sci, 2007,1102(1):26-38.
doi: 10.1196/annals.1408.002 |
[13] |
Chen L, Gui C, Luo X, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro[J]. J Virol, 2005,79(11):7095-7103.
doi: 10.1128/JVI.79.11.7095-7103.2005 pmid: 15890949 |
[14] |
Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions: review of the literature[J]. Eur J Med Res, 2007,12(9):409-417.
pmid: 17933722 |
[15] |
Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells[J]. Cell Stem Cell, 2013,12(3):329-341.
doi: 10.1016/j.stem.2012.12.013 |
[16] |
Andersen PI, Krpina K, Ianevski A, et al. Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine[J]. Viruses, 2019,11(10):964.
doi: 10.3390/v11100964 |
[17] |
Wen CC, Kuo YH, Jan JT, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus[J]. J Med Chem, 2007,50(17):4087-4095.
doi: 10.1021/jm070295s pmid: 17663539 |
[18] |
Aliyari Serej Z, Ebrahimi Kalan A, Mehdipour A, et al. Regulation and roles of CD26/DPPIV in hematopoiesis and diseases[J]. Biomed Pharmacother, 2017,91:88-94.
doi: 10.1016/j.biopha.2017.04.074 pmid: 28448874 |
[19] |
Cheng F, Yuan G, He J, et al. Dysregulation of DPP4 is associa-ted with the AMPK/JAK2/STAT3 pathway in adipocytes under insulin resistance status and liraglutide intervention[J]. Diabetes Metab Syndr Obes, 2019,12:2635-2644.
doi: 10.2147/DMSO.S229838 pmid: 31849507 |
[20] |
Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight[J]. Viruses, 2019,11(1):59.
doi: 10.3390/v11010059 |
[21] |
Li Y, Zhang Z, Yang L, et al. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 Spike[J]. iScience, 2020,23(6):101160.
doi: 10.1016/j.isci.2020.101160 pmid: 32405622 |
[22] |
Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc[J]. Antimicrob Agents Chemother, 2008,52(3):858-865.
doi: 10.1128/AAC.00821-07 pmid: 18070967 |
[23] |
Kitrinos KM, Amrine-Madsen H, Irlbeck DM, et al. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope[J]. Antimicrob Agents Chemother, 2009,53(3):1124-1131.
doi: 10.1128/AAC.01057-08 pmid: 19075068 |
[1] | 杨林承,张瑞涛,郭丽君,肖晗,祖凌云,张幼怡,程秦,赵志伶,葛庆岗,高炜. 低氧状态及炎症反应是新型冠状病毒肺炎患者发生急性心肌损伤的危险因素[J]. 北京大学学报(医学版), 2021, 53(1): 159-166. |
[2] | 吴君怡,余淼,孙仕晨,樊壮壮,郑静蕾,张刘陶,冯海兰,刘洋,韩冬. 少汗性外胚层发育不良患者EDA基因突变检测及表型分析[J]. 北京大学学报(医学版), 2021, 53(1): 24-33. |
[3] | 包芳,史尉利,胡静,张娣,高东晗,夏云霞,景红梅,克晓燕,葛庆岗,沈宁. 新型冠状病毒肺炎淋巴细胞亚群与严重程度的相关分析[J]. 北京大学学报(医学版), 2020, 52(6): 1075-1081. |
[4] | 袁晓宁,孟庆阳,沈宁,李宇轩,梁超,崔曼,葛庆岗,李晓光,谭昆,陈茜,王晶,曾晓勇. 新型冠状病毒肺炎病区环境及医务人员防护设备表面SARS-CoV-2核酸污染的检测与评价[J]. 北京大学学报(医学版), 2020, 52(5): 803-808. |
[5] | 鲍轶,莫娟芬. 同时性多原发肺腺癌组织编码转录因子ERG基因相同位点突变1例报告[J]. 北京大学学报(医学版), 2020, 52(5): 971-974. |
[6] | 王秋,郭金玉,孙红,王泠,应菊素,刘慧鑫. 抗击新型冠状病毒肺炎一线护理人员防护暴露风险事件调查[J]. 北京大学学报(医学版), 2020, 52(4): 711-714. |
[7] | 李秋钰,程秦,赵志伶,代妮妮,曾琳,朱兰,郭炜,李超,王军红,李姝,葛庆岗,沈宁. 肾移植术后感染新型冠状病毒1例[J]. 北京大学学报(医学版), 2020, 52(4): 780-784. |
[8] | 邢燕,张娟,韩彤妍,李在玲,李蕊,童笑梅. 新型冠状病毒感染肺炎疫情下综合医院儿科防控方式探索[J]. 北京大学学报(医学版), 2020, 52(3): 410-413. |
[9] | 陈美恋,高燕,郭维,左力,王天兵. 新型冠状病毒肺炎患者床旁血液净化治疗的感染防控[J]. 北京大学学报(医学版), 2020, 52(3): 414-419. |
[10] | 杨航,杨林承,张瑞涛,凌云鹏,葛庆岗. 合并高血压、冠心病、糖尿病的新型冠状病毒肺炎患者发生病死的危险因素分析[J]. 北京大学学报(医学版), 2020, 52(3): 420-424. |
[11] | 北京大学肿瘤医院新型冠状病毒疫情防控领导小组,季加孚. 北京大学肿瘤医院关于新型冠状病毒疫情期间肿瘤诊治的建议[J]. 北京大学学报(医学版), 2020, 52(2): 199-203. |
[12] | 张宽根,周雨禾,邵雅昆,梅放,由江峰,刘北英,裴斐. 肿瘤转移抑制基因LASS2/TMSG1 S248A突变体通过增加ATP6V0C表达促进前列腺癌的侵袭[J]. 北京大学学报(医学版), 2019, 51(2): 210-220. |
[13] | 王皓,刘洋,刘浩辰,韩冬,冯海兰. 先天性缺牙患者中BMP2基因突变检测及功能分析[J]. 北京大学学报(医学版), 2019, 51(1): 9-15. |
[14] | 尤柱,徐丽莉,李雪芬,张建运,杜菁,孙丽莎. 成釉细胞纤维瘤中BRAF突变基因的检测[J]. 北京大学学报(医学版), 2019, 51(1): 4-5. |
[15] | 刘蕊,翟佳羽,刘湘源,姚中强. 误诊为强直性脊柱炎的进行性假性类风湿发育不良1例[J]. 北京大学学报(医学版), 2018, 50(6): 1112-1116. |
|